Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit .

Related collections

Author and article information

Journal

Title: Journal of the National Comprehensive Cancer Network

Publisher: Harborside Press, LLC

ISSN (Print): 1540-1405

ISSN (Electronic): 1540-1413

Publication date Created: March 11 2019

Publication date (Print): March 11 2019

Volume: 17

Issue: 3

Pages: 255-289

Affiliations

[1 ]1Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

[2 ]2University of Michigan Rogel Cancer Center;

[3 ]3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

[4 ]4Moffitt Cancer Center;

[5 ]5Dana-Farber/Brigham and Women’s Cancer Center;

[6 ]6City of Hope National Medical Center;

[7 ]7University of Alabama at Birmingham Comprehensive Cancer Center;

[8 ]8Yale Cancer Center/Smilow Cancer Hospital;

[9 ]9Patient advocate;

[10 ]10Roswell Park Comprehensive Cancer Center;

[11 ]11Massachusetts General Hospital Cancer Center;

[12 ]12University of Colorado Cancer Center;

[13 ]13Case Comprehensive Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

[14 ]14Memorial Sloan Kettering Cancer Center;

[15 ]15Fred & Pamela Buffett Cancer Center;

[16 ]16Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

[17 ]17Fox Chase Cancer Center;

[18 ]18Vanderbilt-Ingram Cancer Center;

[19 ]19UC San Diego Moores Cancer Center;

[20 ]20Stanford Cancer Institute;

[21 ]21Mayo Clinic Cancer Center;

[22 ]22Duke Cancer Institute;

[23 ]23The University of Texas MD Anderson Cancer Center; and

[24 ]24National Comprehensive Cancer Network.

Article

DOI: 10.6004/jnccn.2019.0013

PubMed ID: 30865922

SO-VID: a2233373-15be-47ae-8030-4c2592fea6cf

History

Data availability:

Comments

Comment on this article

scite_

Cited by 196

See all cited by

- Version 1